Biomarkers for the Early Detection and Progression of Alzheimer's Disease

Repertoires of Autophagy in the Pathogenesis of Ocular Diseases

Li, Y., Jiang, Q. L., Cao, G.-F., Yao, J., & Yan, B. (2015) · Cellular Physiology and Biochemistry · doi:10.1159/000373980 · Cited by 16,351

Neuropathological stageing of Alzheimer-related changes.

Braak, H., & Braak, E. (1991) · Acta Neuropathologica · doi:10.1007/bf00308809 · Cited by 16,123

Toward defining the preclinical stages of Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease

Sperling, R. A., Aisen, P. S., Beckett, L. A., Bennett, D. A., Craft, S., Fagan, A. M., Iwatsubo, T., Jack, C. R., Kaye, J., Montine, T. J., et al. (2011) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.03.003 · Cited by 7,155

Induction of the Vitamin D Receptor Attenuates Autophagy Dysfunction-Mediated Cell Death Following Traumatic Brain Injury

Cui, C., Cui, J., Jin, F., Cui, Y., Li, R., Jiang, X., Tian, Y., Wang, R. C., Jiang, P., & Gao, J. (2017) · Cellular Physiology and Biochemistry · doi:10.1159/000479571 · Cited by 5,214

Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade

Jack, C. R., Knopman, D. S., Jagust, W. J., Shaw, L. M., Aisen, P. S., Weiner, M. W., Petersen, R. C., & Trojanowski, J. Q. (2010) · The Lancet Neurology · doi:10.1016/s1474-4422(09)70299-6 · Cited by 4,806

Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound‐B

Klunk, W. E., Engler, H., Nordberg, A., Wang, Y., Blomqvist, G., Holt, D. P., Bergström, M., Savitcheva, I., Huang, G., Estrada, S., et al. (2004) · Annals of Neurology · doi:10.1002/ana.20009 · Cited by 4,496

The Alzheimer’s disease neuroimaging initiative (ADNI): MRI methods

Jack, C. R., Bernstein, M. A., Fox, N. C., Thompson, P., Alexander, G., Harvey, D., Borowski, B., Britson, P. J., L. Whitwell, J., Ward, C., et al. (2008) · Journal of Magnetic Resonance Imaging · doi:10.1002/jmri.21049 · Cited by 4,347

Phases of Aβ-deposition in the human brain and its relevance for the development of AD

Thal, D. R., Rüb, U., Orantes, M., & Braak, H. (2002) · Neurology · doi:10.1212/wnl.58.12.1791 · Cited by 3,490

The antibody aducanumab reduces Aβ plaques in Alzheimer’s disease

Sevigny, J., Chiao, P., Bussière, T., Weinreb, P. H., Williams, L., Maier, M., Dunstan, R., Salloway, S., Chen, T., Ling, Y., et al. (2016) · Nature · doi:10.1038/nature19323 · Cited by 3,059

Neurofibrillary tangles but not senile plaques parallel duration and severity of Alzheimer's disease

Arriagada, P. V., Growdon, J. H., Hedley-Whyte, E. T., & Hyman, B. T. (1992) · Neurology · doi:10.1212/wnl.42.3.631 · Cited by 2,668

Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects

Shaw, L. M., Vanderstichele, H., Knapik‐Czajka, M., Clark, C. M., Aisen, P. S., Petersen, R. C., Blennow, K., Soares, H., Simon, A., Lewczuk, P., et al. (2009) · Annals of Neurology · doi:10.1002/ana.21610 · Cited by 2,065

The role of autophagy in neurodegenerative disease

Nixon, R. A. (2013) · Nature Medicine · doi:10.1038/nm.3232 · Cited by 2,059

CSF and blood biomarkers for the diagnosis of Alzheimer's disease: a systematic review and meta-analysis

Olsson, B., Lautner, R., Andreasson, U., Öhrfelt, A., Portelius, E., Bjerke, M., Hölttä, M., Rosén, C., Olsson, C., Strobel, G., et al. (2016) · The Lancet Neurology · doi:10.1016/s1474-4422(16)00070-3 · Cited by 2,049

The carboxy terminus of the .beta. amyloid protein is critical for the seeding of amyloid formation: Implications for the pathogenesis of Alzheimer's disease

Jarrett, J. T., Berger, E. P., & Lansbury, P. T. (1993) · Biochemistry · doi:10.1021/bi00069a001 · Cited by 2,022

Mild Cognitive Impairment Represents Early-Stage Alzheimer Disease

Morris, J. C., Storandt, M., Miller, J. P., McKeel, D. W., Price, J. L., Rubin, E. H., & Berg, L. (2001) · Archives of Neurology · doi:10.1001/archneur.58.3.397 · Cited by 1,871

Visualization of Aβ42(43) and Aβ40 in senile plaques with end-specific Aβ monoclonals: Evidence that an initially deposited species is Aβ42(43)

Iwatsubo, T., Odaka, A., Suzuki, N., Mizusawa, H., Nukina, N., & Ihara, Y. (1994) · Neuron · doi:10.1016/0896-6273(94)90458-8 · Cited by 1,774

Isolation and quantification of soluble Alzheimer's β-peptide from biological fluids

Seubert, P., Vigo-Pelfrey, C., Esch, F., Lee, M., Dovey, H., Davis, D., Sinha, S., Schiossmacher, M., Whaley, J., Swindlehurst, C., et al. (1992) · Nature · doi:10.1038/359325a0 · Cited by 1,731

Association between CSF biomarkers and incipient Alzheimer's disease in patients with mild cognitive impairment: a follow-up study

Hansson, O., Zetterberg, H., Buchhave, P., Londos, E., Blennow, K., & Minthon, L. (2006) · The Lancet Neurology · doi:10.1016/s1474-4422(06)70355-6 · Cited by 1,700

Long-term effects of Aβ42 immunisation in Alzheimer's disease: follow-up of a randomised, placebo-controlled phase I trial

Holmes, C., Boche, D., Wilkinson, D., Yadegarfar, G., Hopkins, V., Bayer, A., Jones, R. W., Bullock, R., Love, S., Neal, J. W., et al. (2008) · The Lancet · doi:10.1016/s0140-6736(08)61075-2 · Cited by 1,416

Prediction of AD with MRI-based hippocampal volume in mild cognitive impairment

Jack, C. R., Petersen, R. C., Xu, Y. C., O’Brien, P. C., Smith, G. E., Ivnik, R. J., Boeve, B. F., Waring, S. C., Tangalos, E. G., & Kokmen, E. (1999) · Neurology · doi:10.1212/wnl.52.7.1397 · Cited by 1,404

Preclinical Evidence of Alzheimer's Disease in Persons Homozygous for the ε4 Allele for Apolipoprotein E

Reiman, E. M., Caselli, R. J., Yun, L. S., Chen, K., Bandy, D., Minoshima, S., Thibodeau, S. N., & Osborne, D. (1996) · New England Journal of Medicine · doi:10.1056/nejm199603213341202 · Cited by 1,366

Neuropathology of older persons without cognitive impairment from two community-based studies

Bennett, D. A., Schneider, J. A., Arvanitakis, Z., Kelly, J. F., Aggarwal, N. T., Shah, R. C., & Wilson, R. S. (2006) · Neurology · doi:10.1212/01.wnl.0000219668.47116.e6 · Cited by 1,336

Inverse relation between in vivo amyloid imaging load and cerebrospinal fluid Aβ 42 in humans

Fagan, A. M., Mintun, M. A., Mach, R. H., Lee, S., Dence, C. S., Shah, A. R., LaRossa, G. N., Spinner, M. L., Klunk, W. E., Mathis, C. A., et al. (2006) · Annals of Neurology · doi:10.1002/ana.20730 · Cited by 1,246

PET Imaging of Tau Deposition in the Aging Human Brain

Schöll, M., Lockhart, S. N., Schonhaut, D. R., O’Neil, J. P., Janabi, M., Ossenkoppele, R., Baker, S. L., Vogel, J. W., Faria, J., Schwimmer, H. D., et al. (2016) · Neuron · doi:10.1016/j.neuron.2016.01.028 · Cited by 1,214

CSF Biomarkers and Incipient Alzheimer Disease in Patients With Mild Cognitive Impairment

Mattsson, N. (2009) · JAMA · doi:10.1001/jama.2009.1064 · Cited by 1,176

Use of Florbetapir-PET for Imaging β-Amyloid Pathology

Clark, C. M. (2011) · JAMA · doi:10.1001/jama.2010.2008 · Cited by 1,117

Imaging β-amyloid burden in aging and dementia

Rowe, C. C., Ng, S., Ackermann, U., Gong, S. J., Pike, K., Savage, G., Cowie, T. F., Dickinson, K. L., Maruff, P., Darby, D., et al. (2007) · Neurology · doi:10.1212/01.wnl.0000261919.22630.ea · Cited by 1,104

Plasma phospholipids identify antecedent memory impairment in older adults

Mapstone, M. E., Cheema, A. K., Fiandaca, M. S., Zhong, X., Mhyre, T. R., MacArthur, L. H., Hall, W. J., Fisher, S. G., Peterson, D. R., Haley, J. M., et al. (2014) · Nature Medicine · doi:10.1038/nm.3466 · Cited by 1,060

Classification and prediction of clinical Alzheimer's diagnosis based on plasma signaling proteins

Ray, S., Britschgi, M., Herbert, C., Takeda-Uchimura, Y., Boxer, A., Blennow, K., Friedman, L. F., Galasko, D. R., Jutel, M., Karydas, A., et al. (2007) · Nature Medicine · doi:10.1038/nm1653 · Cited by 1,048

Natural history of mild cognitive impairment in older persons

Bennett, D. A., Wilson, R. S., Schneider, J. A., Evans, D. A., Beckett, L. A., Aggarwal, N. T., Barnes, L. L., Fox, J. H., & Bach, J. (2002) · Neurology · doi:10.1212/wnl.59.2.198 · Cited by 1,037

[ 11 C]PIB in a nondemented population: Potential antecedent marker of Alzheimer disease

Mintun, M. A., LaRossa, G. N., Sheline, Y. I., Dence, C. S., Lee, S. Y., Mach, R. H., Klunk, W. E., Mathis, C. A., DeKosky, S. T., & Morris, J. C. (2006) · Neurology · doi:10.1212/01.wnl.0000228230.26044.a4 · Cited by 1,036

The Alzheimer's Disease Neuroimaging Initiative: A review of papers published since its inception

Weiner, M. W., Veitch, D. P., Aisen, P. S. S., Beckett, L. A., Cairns, N. J., Green, R. C., Harvey, D. J., Jack, C. R., Jagust, W. J., Liu, E., et al. (2013) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2013.05.1769 · Cited by 1,033

Amyloid imaging results from the Australian Imaging, Biomarkers and Lifestyle (AIBL) study of aging

Rowe, C. C., Ellis, K. A., Rimajova, M., Bourgeat, P., Pike, K. E., Jones, G., Fripp, J., Tochon-Danguy, H., Morandeau, L., O'Keefe, G., et al. (2010) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2010.04.007 · Cited by 986

Tau positron emission tomographic imaging in aging and early Alzheimer disease

Johnson, K. A., Schultz, A., Betensky, R. A., Becker, J. A., Sepulcre, J., Rentz, D., Mormino, E., Chhatwal, J., Amariglio, R., Papp, K., et al. (2016) · Annals of Neurology · doi:10.1002/ana.24546 · Cited by 986

Synthesis and Evaluation of 11C-Labeled 6-Substituted 2-Arylbenzothiazoles as Amyloid Imaging Agents

Mathis, C. A., Wang, Y., Holt, D. P., Huang, G.-F., Debnath, M. L., & Klunk, W. E. (2003) · Journal of Medicinal Chemistry · doi:10.1021/jm030026b · Cited by 976

Identification of preclinical Alzheimer's disease by a profile of pathogenic proteins in neurally derived blood exosomes: A case‐control study

Fiandaca, M. S., Kapogiannis, D., Mapstone, M., Boxer, A., Eitan, E., Schwartz, J. B., Abner, E. L., Petersen, R. C., Federoff, H. J., Miller, B. L., et al. (2015) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2014.06.008 · Cited by 959

Rates of hippocampal atrophy correlate with change in clinical status in aging and AD

Jack, C. R., Petersen, R. C., Xu, Y., O’Brien, P. C., Smith, G. E., Ivnik, R. J., Boeve, B. F., Tangalos, E. G., & Kokmen, E. (2000) · Neurology · doi:10.1212/wnl.55.4.484 · Cited by 937

Post-mortem correlates of in vivo PiB-PET amyloid imaging in a typical case of Alzheimer's disease

Ikonomovic, M. D., Klunk, W. E., Abrahamson, E. E., Mathis, C. A., Price, J. C., Tsopelas, N. D., Lopresti, B. J., Ziolko, S., Bi, W., Paljug, W. R., et al. (2008) · Brain · doi:10.1093/brain/awn016 · Cited by 933

Cerebrospinal Fluid tau/β-Amyloid42 Ratio as a Prediction of Cognitive Decline in Nondemented Older Adults

Fagan, A. M., Roe, C. M., Xiong, C., Mintun, M. A., Morris, J. C., & Holtzman, D. M. (2007) · Archives of Neurology · doi:10.1001/archneur.64.3.noc60123 · Cited by 897

Longitudinal assessment of Aβ and cognition in aging and Alzheimer disease

Villemagne, V. L., Pike, K. E., Chételat, G., Ellis, K. A., Mulligan, R. S., Bourgeat, P., Ackermann, U., Jones, G., Szoeke, C., Salvado, O., et al. (2011) · Annals of Neurology · doi:10.1002/ana.22248 · Cited by 833

APOE predicts amyloid‐beta but not tau Alzheimer pathology in cognitively normal aging

Morris, J. C., Roe, C. M., Xiong, C., Fagan, A. M., Goate, A. M., Holtzman, D. M., & Mintun, M. A. (2010) · Annals of Neurology · doi:10.1002/ana.21843 · Cited by 830

Cerebral metabolic and cognitive decline in persons at genetic risk for Alzheimer’s disease

Small, G. W., Ercoli, L. M., Silverman, D. H. S., Huang, S.-C., Komo, S., Bookheimer, S. Y., Lavretsky, H., Miller, K., Siddarth, P., Rasgon, N. L., et al. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.090106797 · Cited by 790

tau protein in cerebrospinal fluid: A biochemical marker for axonal degeneration in Alzheimer disease?

Blennow, K., Wallin, A., Ågren, H., Spenger, C., Siegfried, J., & Vanmechelen, E. (1995) · Molecular and Chemical Neuropathology · doi:10.1007/bf02815140 · Cited by 789

-amyloid imaging and memory in non-demented individuals: evidence for preclinical Alzheimer's disease

Pike, K. E., Savage, G., Villemagne, V. L., Ng, S., Moss, S. A., Maruff, P., Mathis, C. A., Klunk, W. E., Masters, C. L., & Rowe, C. C. (2007) · Brain · doi:10.1093/brain/awm238 · Cited by 789

Antibodies against β-Amyloid Slow Cognitive Decline in Alzheimer's Disease

Höck, C., Konietzko, U., Streffer, J. R., Tracy, J., Signorell, A., Müller-Tillmanns, B., Lemke, U., Henke, K., Moritz, E., Garcia, E., et al. (2003) · Neuron · doi:10.1016/s0896-6273(03)00294-0 · Cited by 786

Fibrillar amyloid-β burden in cognitively normal people at 3 levels of genetic risk for Alzheimer's disease

Reiman, E. M., Chen, K., Liu, X., Bandy, D., Yu, M., Lee, W., Ayutyanont, N., Keppler, J., Reeder, S. A., Langbaum, J. B. S., et al. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0900345106 · Cited by 785

Apolipoprotein E Status as a Predictor of the Development of Alzheimer's Disease in Memory-Impaired Individuals

Petersen, R. C. (1995) · JAMA · doi:10.1001/jama.1995.03520400044042 · Cited by 783

Imaging of Tau Pathology in a Tauopathy Mouse Model and in Alzheimer Patients Compared to Normal Controls

Maruyama, M., Shimada, H., Suhara, T., Shinotoh, H., Ji, B., Maeda, J., Zhang, M.-R., Trojanowski, J. Q., Lee, V. M.-Y., Ono, M., et al. (2013) · Neuron · doi:10.1016/j.neuron.2013.07.037 · Cited by 760

Hippocampal and entorhinal atrophy in mild cognitive impairment

Devanand, D. P., Pradhaban, G., Liu, X., Khandji, A., Santi, S. D., Segal, S., Rusinek, H., Pelton, G. H., Honig, L. S., Mayeux, R. P., et al. (2007) · Neurology · doi:10.1212/01.wnl.0000256697.20968.d7 · Cited by 749

Tau and Aβ imaging, CSF measures, and cognition in Alzheimer’s disease

Brier, M. R., Gordon, B., Friedrichsen, K., McCarthy, J., Stern, A., Christensen, J., Owen, C., Aldea, P., Su, Y., Hassenstab, J., et al. (2016) · Science Translational Medicine · doi:10.1126/scitranslmed.aaf2362 · Cited by 734

PET imaging of amyloid deposition in patients with mild cognitive impairment

Forsberg, A., Engler, H., Almkvist, O., Blomquist, G., Hagman, G., Wall, A. E., Ringheim, A., Långström, B., & Nordberg, A. K. (2007) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2007.03.029 · Cited by 725

In Vivo Imaging of Amyloid Deposition in Alzheimer Disease Using the Radioligand 18 F-AV-45 (Flobetapir F 18)

Wong, D. F., Rosenberg, P. B., Zhou, Y., Kumar, A., Raymont, V., Ravert, H. T., Dannals, R. F., Nandi, A., Brašić, J. R., Ye, W., et al. (2010) · Journal of Nuclear Medicine · doi:10.2967/jnumed.109.069088 · Cited by 684

Episodic memory loss is related to hippocampal-mediated -amyloid deposition in elderly subjects

Mormino, E. C., Kluth, J. T., Madison, C. M., Rabinovici, G. D., Baker, S. L., Miller, B. L., Koeppe, R. A., Mathis, C. A., Weiner, M. W., Jagust, W. J., et al. (2009) · Brain · doi:10.1093/brain/awn320 · Cited by 684

Early Clinical PET Imaging Results with the Novel PHF-Tau Radioligand [F18]-T808

Chien, D. T., Szardenings, A. K., Bahri, S., Walsh, J. C., Mu, F., Xia, C. A., Shankle, W. R., Lerner, A. J., Su, M., Elizarov, A. M., et al. (2013) · Journal of Alzheimer s Disease · doi:10.3233/jad-130098 · Cited by 683

Imaging of amyloid β in Alzheimer's disease with 18F-BAY94-9172, a novel PET tracer: proof of mechanism

Rowe, C. C., Ackerman, U., Browne, W. F., Mulligan, R. S., Pike, K. E., O'Keefe, G. J., Tochon‐Danguy, H., Chan, G., Berlangieri, S. U., Jones, G. R., et al. (2008) · The Lancet Neurology · doi:10.1016/s1474-4422(08)70001-2 · Cited by 680

18 F‐flutemetamol amyloid imaging in Alzheimer disease and mild cognitive impairment: A phase 2 trial

Vandenberghe, R. R., Laere, K. V., Ivanoiu, A., Salmon, É., Bastin, C., Triau, E., Hasselbalch, S. G., Law, I. G., Andersen, A., Kørner, A., et al. (2010) · Annals of Neurology · doi:10.1002/ana.22068 · Cited by 664

Cerebrospinal Fluid Levels ofβ-Amyloid 1-42, but Not of Tau, Are Fully Changed Already 5 to 10 Years Before the Onset of Alzheimer Dementia

Buchhave, P. (2012) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2011.155 · Cited by 664

Cerebrospinal Fluid β-Amyloid(1-42) in Alzheimer Disease: Differences Between Early- and Late-Onset Alzheimer Disease and Stability During the Course of Disease

Andreasen, N., Hesse, C., Davidsson, P., Minthon, L., Wallin, A., Winblad, B., Vanderstichele, H., Vanmechelen, E., & Blennow, K. (1999) · Archives of Neurology · doi:10.1001/archneur.56.6.673 · Cited by 660

Decreased β-Amyloid1-42and Increased Tau Levels in Cerebrospinal Fluid of Patients With Alzheimer Disease

Sunderland, T., Linker, G., Mirza, N., Putnam, K. T., Friedman, D. L., Kimmel, L. H., Bergeson, J., Manetti, G. J., Zimmermann, M., Tang, B., et al. (2003) · JAMA · doi:10.1001/jama.289.16.2094 · Cited by 656

Early clinical PET imaging results with the novel PHF-tau radioligand [F-18]-T807

Chien, D. T., Bahri, S., Szardenings, A. K., Walsh, J. C., Mu, F., Su, M.-Y., Shankle, W. R., Elizarov, A., & Kolb, H. C. (2013) · Journal of Alzheimer's Disease · doi:10.3233/jad-122059 · Cited by 651

Validating novel tau positron emission tomography tracer [F‐18]‐AV‐1451 (T807) on postmortem brain tissue

Marquié, M., Normandin, M. D., Vanderburg, C. R., Costantino, I. M., Bien, E. A., Rycyna, L. G., Klunk, W. E., Mathis, C. A., Ikonomovic, M. D., Debnath, M. L., et al. (2015) · Annals of Neurology · doi:10.1002/ana.24517 · Cited by 615

FDG-PET improves accuracy in distinguishing frontotemporal dementia and Alzheimer's disease

Foster, N. L., Heidebrink, J. L., Clark, C. M., Jagust, W. J., Arnold, S. E., Barbas, N. R., DeCarli, C. S., Scott Turner, R., Koeppe, R. A., Higdon, R., et al. (2007) · Brain · doi:10.1093/brain/awm177 · Cited by 608

Mild cognitive impairment

Chételat, G., Desgranges, B., Sayette, V. D. L., Viader, F., Eustache, F., & Baron, J. (2003) · Neurology · doi:10.1212/01.wnl.0000055847.17752.e6 · Cited by 606

[ 18 F]T807, a novel tau positron emission tomography imaging agent for Alzheimer's disease

Xia, C., Arteaga, J., Chen, G., Gangadharmath, U., Gomez, L. F., Kasi, D., Lam, C., Liang, Q., Liu, C., Mocharla, V. P., et al. (2013) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2012.11.008 · Cited by 605

Florbetaben PET imaging to detect amyloid beta plaques in Alzheimer's disease: Phase 3 study

Sabri, O., Sabbagh, M. N., Seibyl, J., Barthel, H., Akatsu, H., Ouchi, Y., Senda, K., Murayama, S., Ishii, K., Takao, M., et al. (2015) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2015.02.004 · Cited by 602

Cerebral amyloid-β PET with florbetaben (18F) in patients with Alzheimer's disease and healthy controls: a multicentre phase 2 diagnostic study

Barthel, H., Gertz, H., Dresel, S. H. J., Peters, O., Bartenstein, P., Büerger, K., Hiemeyer, F. J., Wittemer‐Rump, S., Seibyl, J. P., Reininger, C. B., et al. (2011) · The Lancet Neurology · doi:10.1016/s1474-4422(11)70077-1 · Cited by 600

Increase of Brain Oxidative Stress in Mild Cognitive Impairment

Praticò, D., Clark, C. M., Liun, F., Lee, V., & Trojanowski, J. Q. (2002) · Archives of Neurology · doi:10.1001/archneur.59.6.972 · Cited by 587

Plasma and Cerebrospinal Fluid Levels of Amyloid β Proteins 1-40 and 1-42 in Alzheimer Disease

Mehta, P. D., Pirttilä, T., Mehta, S. P., Sersen, E. A., Aisen, P. S., & Wisniewski, H. M. (2000) · Archives of Neurology · doi:10.1001/archneur.57.1.100 · Cited by 582

Conversion of Mild Cognitive Impairment to Alzheimer Disease Predicted by Hippocampal Atrophy Maps

Apostolova, L. G., Dutton, R. A., Dinov, I. D., Hayashi, K. M., Toga, A. W., Cummings, J. L., & Thompson, P. M. (2006) · Archives of Neurology · doi:10.1001/archneur.63.5.693 · Cited by 553

Baseline MRI predictors of conversion from MCI to probable AD in the ADNI cohort

Risacher, S., Saykin, A., Wes, J., Shen, L., Firpi, H., & McDonald, B. (2009) · Current Alzheimer Research · doi:10.2174/156720509788929273 · Cited by 538

Mild cognitive impairment is related to Alzheimer disease pathology and cerebral infarctions

Bennett, D. A., Schneider, J. A., Bienias, J. L., Evans, D. A., & Wilson, R. S. (2005) · Neurology · doi:10.1212/01.wnl.0000152982.47274.9e · Cited by 537

YKL-40: A Novel Prognostic Fluid Biomarker for Preclinical Alzheimer's Disease

Craig-Schapiro, R., Perrin, R. J., Roe, C. M., Xiong, C., Carter, D., Cairns, N. J., Mintun, M. A., Peskind, E. R., Li, G., Galasko, D. R., et al. (2010) · Biological Psychiatry · doi:10.1016/j.biopsych.2010.08.025 · Cited by 504

Cerebral amyloid angiopathy: incidence and complications in the aging brain. II. The distribution of amyloid vascular changes.

Vinters, H. V., & Gilbert, J. J. (1983) · Stroke · doi:10.1161/01.str.14.6.924 · Cited by 504

The Precursor Pro-Nerve Growth Factor Is the Predominant Form of Nerve Growth Factor in Brain and Is Increased in Alzheimer's Disease

Fahnestock, M. L., Michalski, B., Xu, B., & Coughlin, M. D. (2001) · Molecular and Cellular Neuroscience · doi:10.1006/mcne.2001.1016 · Cited by 501

Cerebrospinal fluid protein biomarkers for Alzheimer’s disease

Blennow, K. (2004) · Neurotherapeutics · doi:10.1602/neurorx.1.2.213 · Cited by 500

Detection of Proteins in Normal and Alzheimer's Disease Cerebrospinal Fluid with a Sensitive Sandwich Enzyme‐Linked Immunosorbent Assay

Vandermeeren, M., Mercken, M. H., Vanmechelen, E., Six, J., VOORDE, A. V. D., Martin, J., & Cras, P. P. (1993) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.1993.tb09823.x · Cited by 496

Imaging of amyloid burden and distribution in cerebral amyloid angiopathy

Johnson, K. A., Gregas, M., Becker, J. A., Kinnecom, C., Salat, D. H., Moran, E. K., Smith, E. E., Rosand, J., Rentz, D. M., Klunk, W. E., et al. (2007) · Annals of Neurology · doi:10.1002/ana.21164 · Cited by 495

Association of Cerebrospinal Fluid Neurofilament Light Concentration With Alzheimer Disease Progression

Zetterberg, H., Skillbäck, T., Mattsson, N., Trojanowski, J. Q., Portelius, E., Shaw, L. M., Weiner, M. W., Blennow, K., & Initiative, F. T. A. D. N. (2016) · JAMA Neurology · doi:10.1001/jamaneurol.2015.3037 · Cited by 487

Quantification of tau phosphorylated at threonine 181 in human cerebrospinal fluid: a sandwich ELISA with a synthetic phosphopeptide for standardization

Vanmechelen, E., Vanderstichele, H., Davidsson, P., Kerschaver, E. V., Perre, B. V. D., Sjögren, M. J. C., Andreasen, N. C., & Blennow, K. (2000) · Neuroscience Letters · doi:10.1016/s0304-3940(00)01036-3 · Cited by 487

An autoradiographic evaluation of AV-1451 Tau PET in dementia

Lowe, V. J., Curran, G., Fang, P., Liesinger, A. M., Josephs, K. A., Parisi, J. E., Kantarci, K., Boeve, B. F., Pandey, M. K., Bruinsma, T., et al. (2016) · Acta Neuropathologica Communications · doi:10.1186/s40478-016-0315-6 · Cited by 474

Clinical utility of cerebrospinal fluid biomarkers in the diagnosis of early Alzheimer's disease

Blennow, K., Dubois, B., Fagan, A. M., Lewczuk, P., de Leon, M. J., & Hampel, H. J. (2014) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2014.02.004 · Cited by 473

Regional Cerebral Metabolic Alterations in Dementia of the Alzheimer Type

Friedland, R. P., Budinger, T. F., Ganz, E., Yano, Y., Mathis, C. A., Koss, B., Ober, B. A., Huesman, R. H., & Derenzo, S. (1983) · Journal of Computer Assisted Tomography · doi:10.1097/00004728-198308000-00003 · Cited by 468

Neuropathologic Substrate of Mild Cognitive Impairment

Markesbery, W. R., Schmitt, F. A., Kryscio, R. J., Davis, D. G., Smith, C. D., & Wekstein, D. R. (2006) · Archives of Neurology · doi:10.1001/archneur.63.1.38 · Cited by 460

Association of Low Plasma Aβ42/Aβ40 Ratios With Increased Imminent Risk for Mild Cognitive Impairment and Alzheimer Disease

Graff‐Radford, N. R., Crook, J. E., Lucas, J. A., Boeve, B. F., Knopman, D. S., Ivnik, R. J., Smith, G. E., Younkin, L. H., Petersen, R. C., & Younkin, S. G. (2007) · Archives of Neurology · doi:10.1001/archneur.64.3.354 · Cited by 452

Plasma Aβ40 and Aβ42 and Alzheimer’s disease: Relation to age, mortality, and risk

Mayeux, R., Honig, L. S., Tang, M.-X., Manly, J., Stern, Y., Schupf, N., & Mehta, P. D. (2003) · Neurology · doi:10.1212/01.wnl.0000091890.32140.8f · Cited by 434

Blood-Based Protein Biomarkers for Diagnosis of Alzheimer Disease

Doecke, J. D. (2012) · Archives of Neurology · doi:10.1001/archneurol.2012.1282 · Cited by 422

Dissecting phenotypic traits linked to human resilience to Alzheimer’s pathology

Perez-Nievas, B. G., Stein, T. D., Tai, H.-C., Dols-Icardo, O., Scotton, T. C., Barroeta-Espar, I., Fernandez-Carballo, L., de Munain, E. L., Perez, J., Marquie, M., et al. (2013) · Brain · doi:10.1093/brain/awt171 · Cited by 387

Plasma tau levels in Alzheimer's disease

Zetterberg, H., Wilson, D. H., Andréasson, U., Minthon, L., Blennow, K., Randall, J., & Hansson, O. (2013) · Alzheimer s Research & Therapy · doi:10.1186/alzrt163 · Cited by 385

Amyloid Imaging with18F-Florbetaben in Alzheimer Disease and Other Dementias

Villemagne, V. L., Ong, K. T., Mulligan, R. S., Holl, G., Pejoska, S., Jones, G. R., O'Keefe, G. J., Ackerman, U., Tochon‐Danguy, H., Chan, J. G., et al. (2011) · Journal of Nuclear Medicine · doi:10.2967/jnumed.111.089730 · Cited by 378

Detailed comparison of amyloid PET and CSF biomarkers for identifying early Alzheimer disease

Palmqvist, S., Zetterberg, H., Mattsson, N., Johansson, P., Initiative, F. T. A. D. N., Minthon, L., Blennow, K., Olsson, M., For the Swedish BioFINDER study group, Hansson, O., et al. (2015) · Neurology · doi:10.1212/wnl.0000000000001991 · Cited by 375

Relationship between atrophy and β‐amyloid deposition in Alzheimer disease

Chételat, G., Villemagne, V. L., Bourgeat, P., Pike, K. E., Jones, G., Ames, D., Ellis, K. A., Szoeke, C., Martins, R. N., O'Keefe, G. J., et al. (2010) · Annals of Neurology · doi:10.1002/ana.21955 · Cited by 373

Using Positron Emission Tomography and Florbetapir F 18 to Image Cortical Amyloid in Patients With Mild Cognitive Impairment or Dementia Due to Alzheimer Disease

Fleisher, A. S. (2011) · Archives of Neurology · doi:10.1001/archneurol.2011.150 · Cited by 364

Cerebrospinal fluid levels of the synaptic protein neurogranin correlates with cognitive decline in prodromal Alzheimer's disease

Kvartsberg, H., Duits, F. H., Ingelsson, M., Andreasen, N., Öhrfelt, A., Andersson, K., Brinkmalm, G., Lannfelt, L., Minthon, L., Hansson, O., et al. (2014) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2014.10.009 · Cited by 349

2014 Update of the Alzheimer’s Disease Neuroimaging Initiative: A review of papers published since its inception

Weiner, M. W., Veitch, D. P., Aisen, P. S., Beckett, L. A., Cairns, N. J., Cedarbaum, J., Green, R. C., Harvey, D., Jack, C. R., Jagust, W., et al. (2015) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2014.11.001 · Cited by 348

MCI conversion to dementia and the APOE genotype

Mosconi, L., Perani, D., Sorbi, S., Herholz, K., Nacmias, B., Holthoff‐Detto, V., Salmon, É., Baron, J., Cristofaro, M. T. D., Padovani, A., et al. (2004) · Neurology · doi:10.1212/01.wnl.0000147469.18313.3b · Cited by 347

Molecular imaging with Pittsburgh Compound B confirmed at autopsy: a case report.

Bacskai, B. J., Frosch, M. P., Freeman, S. H., Raymond, S. B., Augustinack, J. C., Johnson, K. A., Irizarry, M. C., Klunk, W. E., Mathis, C. A., DeKosky, S. T., et al. (2007) · PubMed · doi:10.1001/archneur.64.3.431 · Cited by 341

Phase 1 Study of the Pittsburgh Compound B Derivative 18 F-Flutemetamol in Healthy Volunteers and Patients with Probable Alzheimer Disease

Nelissen, N., Laere, K. V., Thurfjell, L., Owenius, R., Vandenbulcke, M., Koole, M. J. B., Bormans, G. M., Brooks, D. J., & Vandenberghe, R. R. (2009) · Journal of Nuclear Medicine · doi:10.2967/jnumed.109.063305 · Cited by 335

Phase 3 Trial of Flutemetamol Labeled With Radioactive Fluorine 18 Imaging and Neuritic Plaque Density

Curtis, C., Gamez, J. E., Singh, U., Sadowsky, C. H., Villena, T., Sabbagh, M. N., Beach, T. G., Duara, R., Fleisher, A. S., Frey, K. A., et al. (2015) · JAMA Neurology · doi:10.1001/jamaneurol.2014.4144 · Cited by 332

MRI-derived entorhinal volume is a good predictor of conversion from MCI to AD

deToledo‐Morrell, L., Stoub, T. R., Bulgakova, M., Wilson, R. S., Bennett, D. A., Leurgans, S. E., Wuu, J., & Turner, D. A. (2004) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2003.12.007 · Cited by 330

18F-THK5351: A Novel PET Radiotracer for Imaging Neurofibrillary Pathology in Alzheimer Disease

Harada, R., Okamura, N., Furumoto, S., Furukawa, K., Ishiki, A., Tomita, N., Tago, T., Hiraoka, K., Watanuki, S., Shidahara, M., et al. (2016) · Journal of Nuclear Medicine · doi:10.2967/jnumed.115.164848 · Cited by 330

Heterogeneity of Brain Glucose Metabolism in Mild Cognitive Impairment and Clinical Progression to Alzheimer Disease

Anchisi, D., Borroni, B., Franceschi, M., Kerrouche, N., Kalbe, E., Beuthien-Beumann, B., Cappa, S. F., Lenz, O., Lüdecke, S., Marcone, A., et al. (2005) · Archives of Neurology · doi:10.1001/archneur.62.11.1728 · Cited by 320

Intravenous immunoglobulins containing antibodies against -amyloid for the treatment of Alzheimer's disease

Dodel, R. C. (2004) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp.2003.033399 · Cited by 319

The cerebrospinal fluid “Alzheimer profile”: Easily said, but what does it mean?

Duits, F. H., Teunissen, C. E., Bouwman, F. H., Visser, P. J., Mattsson, N., Zetterberg, H., Blennow, K., Hansson, O., Minthon, L., Andreasen, N., et al. (2014) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2013.12.023 · Cited by 311

Update on the biomarker core of the Alzheimer's Disease Neuroimaging Initiative subjects

Trojanowski, J. Q., Vandeerstichele, H., Korecka, M., Clark, C. M., Aisen, P. S. S., Petersen, R. C., Blennow, K., Soares, H. D., Simon, A. J., Lewczuk, P., et al. (2010) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2010.03.008 · Cited by 309

Cognitive Decline and Brain Volume Loss as Signatures of Cerebral Amyloid-β Peptide Deposition Identified With Pittsburgh Compound B

Storandt, M., Mintun, M. A., Head, D. M., & Morris, J. C. (2009) · Archives of Neurology · doi:10.1001/archneurol.2009.272 · Cited by 309

PET amyloid ligand [ 11 C]PIB uptake is increased in mild cognitive impairment

Kemppainen, N. M., Aalto, S., Wilson, I. A., Någren, K., Helin, S., Brück, A., Oikonen, V., Kailajärvi, M., Scheinin, M., Viitanen, M. H., et al. (2007) · Neurology · doi:10.1212/01.wnl.0000260969.94695.56 · Cited by 307

Amyloid PET imaging in Alzheimer’s disease: a comparison of three radiotracers

Initiative, T. A. D. N., Landau, S. M., Thomas, B. A., Thurfjell, L., Schmidt, M. E., Margolin, R. A., Mintun, M. A., Pontecorvo, M. J., Baker, S. L., & Jagust, W. J. (2014) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-014-2753-3 · Cited by 306

What does fluorodeoxyglucose PET imaging add to a clinical diagnosis of dementia?

Jagust, W. J., Reed, B., Mungas, D., Ellis, W. G., & DeCarli, C. S. (2007) · Neurology · doi:10.1212/01.wnl.0000269790.05105.16 · Cited by 303

Aβ deposits in older non-demented individuals with cognitive decline are indicative of preclinical Alzheimer's disease

Villemagne, V. L., Pike, K. E., Darby, D., Maruff, P. T., Savage, G. R., Ng, S., Ackermann, U., Cowie, T., Currie, J. N., Chan, S. G., et al. (2008) · Neuropsychologia · doi:10.1016/j.neuropsychologia.2008.02.008 · Cited by 302

PIB is a non-specific imaging marker of amyloid-beta (A ) peptide-related cerebral amyloidosis

Lockhart, A., Lamb, J. R., Osredkar, T., Sue, L. I., Joyce, J. N., Ye, L., Libri, V., Leppert, D., & Beach, T. G. (2007) · Brain · doi:10.1093/brain/awm191 · Cited by 302

Impaired cerebral glucose metabolism and cognitive functioning predict deterioration in mild cognitive impairment

Arnáiz, E., Jelic, V., Almkvist, O., Wahlund, L.-O., Winblad, B., Valind, S., & Nordberg, A. (2001) · Neuroreport · doi:10.1097/00001756-200103260-00045 · Cited by 302

Longitudinal Cerebrospinal Fluid Biomarker Changes in Preclinical Alzheimer Disease During Middle Age

Sutphen, C. L., Jasielec, M. S., Shah, A. R., Macy, E. M., Xiong, C., Vlassenko, A. G., Benzinger, T. L. S., Stoops, E., Vanderstichele, H., Brix, B., et al. (2015) · JAMA Neurology · doi:10.1001/jamaneurol.2015.1285 · Cited by 301

Qualification of the analytical and clinical performance of CSF biomarker analyses in ADNI

Initiative, T. A. D. N., Shaw, L. M. J., Vanderstichele, H., Knapik-Czajka, M. E., Figurski, M., Coart, E., Blennow, K., Soares, H. D., Simon, A. J., Lewczuk, P., et al. (2011) · Acta Neuropathologica · doi:10.1007/s00401-011-0808-0 · Cited by 301

Evaluation of Tau Imaging in Staging Alzheimer Disease and Revealing Interactions Between β-Amyloid and Tauopathy

Wang, L. Y., Benzinger, T. L. S., Su, Y., Christensen, J. J., Friedrichsen, K. A., Aldea, P., McConathy, J., Cairns, N. J., Fagan, A. M., Morris, J. C., et al. (2016) · JAMA Neurology · doi:10.1001/jamaneurol.2016.2078 · Cited by 301

Guidelines for the standardization of preanalytic variables for blood‐based biomarker studies in Alzheimer's disease research

O’Bryant, S. E., Gupta, V. B., Henriksen, K., Edwards, M., Jeromin, A., Lista, S., Bazenet, C. E., Soares, H. D., Lovestone, S., Hampel, H. J., et al. (2014) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2014.08.099 · Cited by 294

SNAP-25 is a promising novel cerebrospinal fluid biomarker for synapse degeneration in Alzheimer’s disease

Brinkmalm, A., Brinkmalm, G., Honer, W. G., Frölich, L., Hausner, L., Minthon, L., Hansson, O., Wallin, A., Zetterberg, H., Blennow, K., et al. (2014) · Molecular Neurodegeneration · doi:10.1186/1750-1326-9-53 · Cited by 293

Preclinical Alzheimer disease—the challenges ahead

Sperling, R. A., Karlawish, J., & Johnson, K. A. (2013) · Nature Reviews Neurology · doi:10.1038/nrneurol.2012.241 · Cited by 291

Increased metabolic vulnerability in early-onset Alzheimer’s disease is not related to amyloid burden

Rabinovici, G. D., Furst, A. J., Alkalay, A., Racine, C. A., O’Neil, J. P., Janabi, M., Baker, S. L., Agarwal, N., Bonasera, S. J., Mormino, E. C., et al. (2010) · Brain · doi:10.1093/brain/awp326 · Cited by 289

Longitudinal cognitive decline is associated with fibrillar amyloid-beta measured by [ 11 C]PiB

Resnick, S. M., Sojkova, J., Zhou, Y., An, Y., Ye, W., Holt, D. P., Dannals, R. F., Mathis, C. A., Klunk, W. E., Ferrucci, L., et al. (2010) · Neurology · doi:10.1212/wnl.0b013e3181d3e3e9 · Cited by 288

Cerebrospinal fluid neurogranin: relation to cognition and neurodegeneration in Alzheimer’s disease

Portelius, E., Zetterberg, H., Skillbäck, T., Törnqvist, U., Andreasson, U., Trojanowski, J. Q., Weiner, M. W., Shaw, L. M., & Mattsson, N. (2015) · Brain · doi:10.1093/brain/awv267 · Cited by 279

Regional analysis of FDG and PIB-PET images in normal aging, mild cognitive impairment, and Alzheimer's disease

Li, Y., Rinne, J. O., Mosconi, L., Pirraglia, E., Rusinek, H., DeSanti, S., Kemppainen, N., Någren, K., Kim, B.-C., Tsui, W., et al. (2008) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-008-0833-y · Cited by 278

Beta Amyloid in Alzheimer's Disease: Increased Deposition in Brain Is Reflected in Reduced Concentration in Cerebrospinal Fluid

Grimmer, T., Riemenschneider, M., Förstl, H., Henriksen, G., Klunk, W. E., Mathis, C. A., Shiga, T., Wester, H.-J., Kurz, A., & Drzezga, A. (2009) · Biological Psychiatry · doi:10.1016/j.biopsych.2009.01.027 · Cited by 278

Prediction of individual clinical outcome in MCI by means of genetic assessment and (18)F-FDG PET.

Drzezga, A. E., Grimmer, T., Riemenschneider, M., Lautenschlager, N. T., Siebner, H. R., Alexopoulus, P., Minoshima, S., Schwaiger, M., & Kurz, A. (2005) · PubMed · Cited by 277

Longitudinal MRI atrophy biomarkers: Relationship to conversion in the ADNI cohort

Risacher, S. L., Shen, L., West, J. D., Kim, S., McDonald, B. C., Beckett, L. A., Harvey, D. J., Jack, C. R., Weiner, M. W., & Saykin, A. J. (2010) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2010.04.029 · Cited by 276

Tau PET in Alzheimer disease and mild cognitive impairment

Cho, H., Choi, J. Y., Hwang, M. S., Lee, J., Kim, Y. J., Lee, H., Lyoo, C. H., Ryu, Y. H., & Lee, M. S. (2016) · Neurology · doi:10.1212/wnl.0000000000002892 · Cited by 274

Biomarkers of Alzheimer disease in plasma

Irizarry, M. C. (2004) · NeuroRx · doi:10.1602/neurorx.1.2.226 · Cited by 273

Non-invasive assessment of Alzheimer’s disease neurofibrillary pathology using 18F-THK5105 PET

Okamura, N., Furumoto, S., Fodero‐Tavoletti, M. T., Mulligan, R. S., Harada, R., Yates, P. A., Pejoska, S., Kudo, Y., Masters, C. L., Yanai, K., et al. (2014) · Brain · doi:10.1093/brain/awu064 · Cited by 273

CSF Multianalyte Profile Distinguishes Alzheimer and Parkinson Diseases

Zhang, J., Sokal, I., Peskind, E. R., Quinn, J. F., Jankovic, J. J., Kenney, C., Chung, K. A., Millard, S. P., Nutt, J. G., & Montine, T. J. (2008) · American Journal of Clinical Pathology · doi:10.1309/w01y0b808emeh12l · Cited by 265

Dissociating atrophy and hypometabolism impact on episodic memory in mild cognitive impairment

Chetelat, G. (2003) · Brain · doi:10.1093/brain/awg196 · Cited by 264

CSF neurofilament light differs in neurodegenerative diseases and predicts severity and survival

Skillbäck, T., Farahmand, B., Bartlett, J. W., Rosén, C., Mattsson, N., Nägga, K., Kilander, L., Religa, D., Wimo, A., Winblad, B., et al. (2014) · Neurology · doi:10.1212/wnl.0000000000001015 · Cited by 263

Using PET with 18F-AV-45 (florbetapir) to quantify brain amyloid load in a clinical environment

Camus, V., Payoux, P., Barré, L., Desgranges, B., Voisin, T., Tauber, C., Joie, R. L., Tafani, M., Hommet, C., Chételat, G., et al. (2012) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-011-2021-8 · Cited by 257

Increased CSF F 2 -isoprostane concentration in probable AD

Montine, T. J., Beal, M. F., Cudkowicz, M., O’Donnell, H., Margolin, R. A., McFarland, L. L., Bachrach, A., Zackert, W. E., Roberts, L. J., & Morrow, J. D. (1999) · Neurology · doi:10.1212/wnl.52.3.562 · Cited by 251

Proteomic studies of potential cerebrospinal fluid protein markers for Alzheimer’s disease.

Puchades, M., Hansson, S. F., Nilsson, C. L., Andreasen, N., Blennow, K., & Davidsson, P. (2003) · Molecular Brain Research · doi:10.1016/j.molbrainres.2003.08.005 · Cited by 245

Automated mapping of hippocampal atrophy in 1-year repeat MRI data from 490 subjects with Alzheimer's disease, mild cognitive impairment, and elderly controls

Morra, J. H., Tu, Z., Apostolova, L. G., Green, A. E., Avedissian, C., Madsen, S. K., Parikshak, N., Toga, A. W., Jack, C. R., Schuff, N. W., et al. (2008) · NeuroImage · doi:10.1016/j.neuroimage.2008.10.043 · Cited by 244

Microarray Analysis of Hippocampal CA1 Neurons Implicates Early Endosomal Dysfunction During Alzheimer's Disease Progression

Ginsberg, S. D., Alldred, M. J., Counts, S. E., Cataldo, A. M., Neve, R. L., Jiang, Y., Wuu, J., Chao, M. V., Mufson, E. J., Nixon, R. A., et al. (2010) · Biological Psychiatry · doi:10.1016/j.biopsych.2010.05.030 · Cited by 243

Entorhinal Cortex β-Amyloid Load in Individuals with Mild Cognitive Impairment

Mufson, E. J., Chen, E.-Y., Cochran, E. J., Beckett, L. A., Bennett, D. A., & Kordower, J. H. (1999) · Experimental Neurology · doi:10.1006/exnr.1999.7086 · Cited by 241

Basal Cerebral Metabolism May Modulate the Cognitive Effects of Aβ in Mild Cognitive Impairment: An Example of Brain Reserve

Cohen, A. D., Price, J. C., Weissfeld, L. A., James, J. A., Rosario, B. L., Bi, W., Nebes, R. D., Saxton, J. A., Snitz, B. E., Aizenstein, H. J., et al. (2009) · Journal of Neuroscience · doi:10.1523/jneurosci.3669-09.2009 · Cited by 240

Plasma multianalyte profiling in mild cognitive impairment and Alzheimer disease

Hu, W. T., Holtzman, D. M., Fagan, A. M., Shaw, L. M. J., Perrin, R. J., Arnold, S. E., Grossman, M., Xiong, C., Craig‐Schapiro, R., Clark, C. M., et al. (2012) · Neurology · doi:10.1212/wnl.0b013e318266fa70 · Cited by 237

MicroRNA Profiling of CSF Reveals Potential Biomarkers to Detect Alzheimer`s Disease

Denk, J., Boelmans, K., Siegismund, C., Lassner, D., Arlt, S., & Jahn, H. (2015) · PLOS ONE · doi:10.1371/journal.pone.0126423 · Cited by 236

Increased proNGF Levels in Subjects with Mild Cognitive Impairment and Mild Alzheimer Disease

Peng, S., Wuu, J., Mufson, E. J., & Fahnestock, M. L. (2004) · Journal of Neuropathology & Experimental Neurology · doi:10.1093/jnen/63.6.641 · Cited by 236

Cerebrospinal Fluid Biomarkers and Rate of Cognitive Decline in Very Mild Dementia of the Alzheimer Type

Snider, B. J., Fagan, A. M., Roe, C. M., Shah, A. R., Grant, E., Xiong, C., Morris, J. C., & Holtzman, D. M. (2009) · Archives of Neurology · doi:10.1001/archneurol.2009.55 · Cited by 229

Diagnostic and Prognostic Utility of the Synaptic Marker Neurogranin in Alzheimer Disease

Tarawneh, R. M., D’Angelo, G., Crimmins, D. L., Herries, E. M., Griest, T. A., Fagan, A. M., Zipfel, G. J., Ladenson, J. H., Morris, J. C., & Holtzman, D. M. (2016) · JAMA Neurology · doi:10.1001/jamaneurol.2016.0086 · Cited by 228

Brain Volume Decline in Aging

Fotenos, A. F., Mintun, M. A., Snyder, A. Z., Morris, J. C., & Buckner, R. L. (2008) · Archives of Neurology · doi:10.1001/archneurol.2007.27 · Cited by 226

Elevation of microtubule-associated protein tau in the cerebrospinal fluid of patients with Alzheimer's disease

Vigo‐Pelfrey, C., Seubert, P., Barbour, R., Blomquist, C., Lee, M., Lee, D., Coria, F., Chang, L., Miller, B. L., Lieberburg, I. M., et al. (1995) · Neurology · doi:10.1212/wnl.45.4.788 · Cited by 225

The Role of Nerve Growth Factor Receptors in Cholinergic Basal Forebrain Degeneration in Prodromal Alzheimer Disease

Counts, S., & Mufson, E. J. (2005) · Journal of Neuropathology & Experimental Neurology · doi:10.1093/jnen/64.4.263 · Cited by 223

Cerebrospinal Fluid Tau and β-Amyloid 42 Proteins Identify Alzheimer Disease in Subjects With Mild Cognitive Impairment

Riemenschneider, M. J., Lautenschlager, N. T., Wagenpfeil, S., Diehl, J., Drzezga, A. E., & Kurz, A. (2002) · Archives of Neurology · doi:10.1001/archneur.59.11.1729 · Cited by 218

Education and occupation as proxies for reserve in aMCI converters and AD: FDG-PET evidence

Garibotto, V., Borroni, B., Kalbe, E., Herholz, K., Salmon, E., Holtoff, V., Sorbi, S., Cappa, S. F., Padovani, A., Fazio, F., et al. (2008) · Neurology · doi:10.1212/01.wnl.0000327670.62378.c0 · Cited by 218

Early detection of Alzheimer's disease using PiB and FDG PET

Cohen, A. D., & Klunk, W. E. (2014) · Neurobiology of Disease · doi:10.1016/j.nbd.2014.05.001 · Cited by 216

Association of brain amyloid-β with cerebral perfusion and structure in Alzheimer’s disease and mild cognitive impairment

Mattsson, N., Tosun, D., Insel, P. S., Simonson, A., Jack, C. R., Beckett, L. A., Donohue, M., Jagust, W., Schuff, N. W., & Weiner, M. W. (2014) · Brain · doi:10.1093/brain/awu043 · Cited by 216

Absence of Pittsburgh Compound B Detection of Cerebral Amyloid β in a Patient With Clinical, Cognitive, and Cerebrospinal Fluid Markers of Alzheimer Disease

Cairns, N. J., Ikonomović, M. D., Benzinger, T. L. S., Storandt, M., Fagan, A. M., Shah, A. R., Taylor‐Reinwald, L., Carter, D. R., Felton, A., Holtzman, D. M., et al. (2009) · Archives of Neurology · doi:10.1001/archneurol.2009.279 · Cited by 205

Imaging of amyloid plaques and cerebral glucose metabolism in semantic dementia and Alzheimer’s disease

Drzezga, A. E., Grimmer, T., Henriksen, G., Stangier, I., Perneczky, R., Diehl‐Schmid, J., Mathis, C. A., Klunk, W. E., Price, J. C., & DeKosky, S. T. (2007) · NeuroImage · doi:10.1016/j.neuroimage.2007.09.020 · Cited by 205

Decreased levels of soluble amyloid beta-protein precursor in cerebrospinal fluid of live Alzheimer disease patients.

Nostrand, W. E. V., Wagner, S. L., Shankle, W. R., Farrow, J. S., Dick, M. B., Rozemüller, A. J. M., Kuiper, M. A., Wolters, E. C., Zimmerman, J. B., & Cotman, C. W. (1992) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.89.7.2551 · Cited by 205

Biochemical diagnosis of Alzheimer disease by measuring the cerebrospinal fluid ratio of phosphorylated tau protein to β-amyloid peptide42

Maddalena, A., Papassotiropoulos, A., Müller-Tillmanns, B., Jung, H. H., Hegi, T., Nitsch, R. M., & Hock, C. (2003) · Archives of Neurology · doi:10.1001/archneur.60.9.1202 · Cited by 204

Plasma Concentrations of Vitamins A and E and Carotenoids in Alzheimer's Disease

Zaman, Z., ROCHE, S., FIELDEN, P., Frost, P., Niriella, D. C., & CAYLEY, A. C. D. (1992) · Age and Ageing · doi:10.1093/ageing/21.2.91 · Cited by 202

Comparison of 18F-FDG and PiB PET in Cognitive Impairment

Lowe, V. J., Kemp, B. J., Jack, C. R., Senjem, M. L., Weigand, S. D., Shiung, M. S., Smith, G. E., Knopman, D. S., Boeve, B. F., Mullan, B. P., et al. (2009) · Journal of Nuclear Medicine · doi:10.2967/jnumed.108.058529 · Cited by 196

Metabolomics of Human Brain Aging and Age-Related Neurodegenerative Diseases

Jové, M., Portero-Otín, M., Naudí, A., Ferrer, I., & Pamplona, R. (2014) · Journal of Neuropathology & Experimental Neurology · doi:10.1097/nen.0000000000000091 · Cited by 195

Amyloid PET imaging in patients with mild cognitive impairment: A 2-year follow-up study

Koivunen, J., Scheinin, N., Virta, J. R., Aalto, S., Vahlberg, T., Någren, K., Helin, S., Parkkola, R., Viitanen, M., & Rinne, J. O. (2011) · Neurology · doi:10.1212/wnl.0b013e318212015e · Cited by 188

CSF tau protein phosphorylated at threonine 231 correlates with cognitive decline in MCI subjects

Buerger, K., Teipel, S. J., Zinkowski, R., Blennow, K., Arai, H., Engel, R., Hofmann–Kiefer, K., McCulloch, C., Ptok, U., Heun, R., et al. (2002) · Neurology · doi:10.1212/wnl.59.4.627 · Cited by 187

Characterization of tau positron emission tomography tracer [18F]AV‐1451 binding to postmortem tissue in Alzheimer's disease, primary tauopathies, and other dementias

Sander, K., Lashley, T., Gami, P., Gendron, T., Lythgoe, M. F., Rohrer, J. D., Schott, J. M., Revesz, T., Fox, N. C., & Årstad, E. (2016) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2016.01.003 · Cited by 187

Discovery of 6-(Fluoro- 18 F )-3-(1 H -pyrrolo[2,3- c ]pyridin-1-yl)isoquinolin-5-amine ([ 18 F]-MK-6240): A Positron Emission Tomography (PET) Imaging Agent for Quantification of Neurofibrillary Tangles (NFTs)

Walji, A. M., Hostetler, E. D., Selnick, H. G., Zeng, Z., Miller, P. J., Bennacef, I., Salinas, C. A., Connolly, B., Gantert, L. T., Holahan, M. A., et al. (2016) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6b00166 · Cited by 185

Longitudinal change in CSF Tau and Aβ biomarkers for up to 48 months in ADNI

Toledo, J. B., Xie, S. X., Trojanowski, J. Q., & Shaw, L. M. (2013) · Acta Neuropathologica · doi:10.1007/s00401-013-1151-4 · Cited by 180

Levels of Nonphosphorylated and Phosphorylated Tau in Cerebrospinal Fluid of Alzheimer's Disease Patients

Hu, Y., He, S., Wang, X., Duan, Q., Grundke, I., Iqbal, K., & Wang, J. (2002) · American Journal Of Pathology · doi:10.1016/s0002-9440(10)62554-0 · Cited by 180

Amyloid load and cerebral atrophy in Alzheimer's disease: An 11C‐PIB positron emission tomography study

Archer, H. A., Edison, P., Brooks, D. J., Barnes, J., Frost, C. D., Yeatman, T., Fox, N. C., & Rossor, M. N. (2006) · Annals of Neurology · doi:10.1002/ana.20889 · Cited by 179

Diagnosis of Parkinson's Disease Based on Disease-Specific Autoantibody Profiles in Human Sera

Han, M. C., Nagele, E. P., DeMarshall, C. A., Acharya, N. K., & Nagele, R. G. (2012) · PLoS ONE · doi:10.1371/journal.pone.0032383 · Cited by 179

Association between genetic traits for immune-mediated diseases and Alzheimer disease

Yokoyama, J. S., Wang, Y., Schork, A. J., Thompson, W. K., Karch, C. M., Cruchaga, C., McEvoy, L. K., Witoelar, A., Chen, C.-H., Holland, D., et al. (2016) · JAMA Neurology · doi:10.1001/jamaneurol.2016.0150 · Cited by 176

Identification and Validation of Novel Cerebrospinal Fluid Biomarkers for Staging Early Alzheimer's Disease

Perrin, R. J., Craig‐Schapiro, R., Malone, J. P., Shah, A. R., Erdmann-Gilmore, P., Davis, A., Roe, C. M., Peskind, E. R., Li, G., Galasko, D. R., et al. (2011) · PLoS ONE · doi:10.1371/journal.pone.0016032 · Cited by 175

Detection of tau phosphorylated at threonine 231 in cerebrospinal fluid of Alzheimer's disease patients

Kohnken, R. E., Büerger, K., Zinkowski, R. P., Miller, C., Kerkman, D. J., DeBernardis, J. F., Shen, J., Möller, H., Davies, P., & Hampel, H. J. (2000) · Neuroscience Letters · doi:10.1016/s0304-3940(00)01178-2 · Cited by 173

In vivo evaluation of a novel tau imaging tracer for Alzheimer’s disease

Villemagne, V. L., Furumoto, S., Fodero‐Tavoletti, M. T., Mulligan, R. S., Hodges, J. R., Harada, R., Yates, P. A., Piguet, O., Pejoska, S., Doré, V., et al. (2014) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-013-2681-7 · Cited by 173

A worldwide multicentre comparison of assays for cerebrospinal fluid biomarkers in Alzheimer's disease

Verwey, N. A., van der Flier, W. M., Blennow, K., Clark, C. M., Sokolow, S., Deyn, P. P. D., Galasko, D. R., Hampel, H. J., Hartmann, T., Kapaki, E., et al. (2009) · Annals of Clinical Biochemistry International Journal of Laboratory Medicine · doi:10.1258/acb.2009.008232 · Cited by 171

Visinin‐like protein‐1: Diagnostic and prognostic biomarker in Alzheimer disease

Tarawneh, R. M., D’Angelo, G., Macy, E., Xiong, C., Carter, D. R., Cairns, N. J., Fagan, A. M., Head, D. M., Mintun, M. A., Ladenson, J. H., et al. (2011) · Annals of Neurology · doi:10.1002/ana.22448 · Cited by 169

18 F-AV-1451 tau PET imaging correlates strongly with tau neuropathology in MAPT mutation carriers

Smith, R., Puschmann, A., Schöll, M., Ohlsson, T., van Swieten, J., Honer, M., Englund, E., & Hansson, O. (2016) · Brain · doi:10.1093/brain/aww163 · Cited by 168

In vivo amyloid imaging in autopsy-confirmed Parkinson disease with dementia

Burack, M. A., Hartlein, J. M., Flores, H., Taylor-Reinwald, L., Perlmutter, J. S., & Cairns, N. J. (2009) · Neurology · doi:10.1212/wnl.0b013e3181c7da8e · Cited by 165

Subgroups of Alzheimer's disease based on cerebrospinal fluid molecular markers

Iqbal, K., Flory, M. J., Khatoon, S., Soininen, H. S., Pirttilä, T., Lehtovirta, M., Alafuzoff, I. I., Blennow, K., Andreasen, N., Vanmechelen, E., et al. (2005) · Annals of Neurology · doi:10.1002/ana.20639 · Cited by 164

Not quite PIB-positive, not quite PIB-negative: Slight PIB elevations in elderly normal control subjects are biologically relevant

Mormino, E. C., Brandel, M. G., Madison, C. M., Rabinovici, G. D., Marks, S., Baker, S. L., & Jagust, W. J. (2012) · NeuroImage · doi:10.1016/j.neuroimage.2011.07.098 · Cited by 158

In VitroCharacterization of Pittsburgh Compound-B Binding to Lewy Bodies

Fodero‐Tavoletti, M. T., Smith, D. P., McLean, C., Adlard, P. A., Barnham, K. J., Foster, L. E., Leone, L., Perez, K. A., Cortés, M., Culvenor, J. G., et al. (2007) · Journal of Neuroscience · doi:10.1523/jneurosci.0630-07.2007 · Cited by 157

11 C-PIB binding is increased in patients with cerebral amyloid angiopathy–related hemorrhage

Ly, J. V., Donnan, G. A., Villemagne, V. L., Zavala, J. A., Ma, H., O'Keefe, G., Gong, S. J., Gunawan, R. M., Saunder, T., Ackerman, U., et al. (2010) · Neurology · doi:10.1212/wnl.0b013e3181cef7e3 · Cited by 157

A Blood-Based Screening Tool for Alzheimer's Disease That Spans Serum and Plasma: Findings from TARC and ADNI

O’Bryant, S. E., Xiao, G., Barber, R. C., Huebinger, R. M., Wilhelmsen, K. C., Edwards, M., Graff‐Radford, N. R., Doody, R. S., Diaz-Arrastia, R. R., & Initiative, A. D. N. (2011) · PLoS ONE · doi:10.1371/journal.pone.0028092 · Cited by 156

Reduced expression of hsa-miR-27a-3p in CSF of patients with Alzheimer disease

Sala Frigerio, C., Lau, P., Salta, E., Tournoy, J., Bossers, K., Vandenberghe, R., Wallin, A., Bjerke, M., Zetterberg, H., Blennow, K., et al. (2013) · Neurology · doi:10.1212/01.wnl.0000437306.37850.22 · Cited by 156

Biological Marker Candidates of Alzheimer's Disease in Blood, Plasma, and Serum

Schneider, P., Hampel, H. J., & Büerger, K. (2009) · CNS Neuroscience & Therapeutics · doi:10.1111/j.1755-5949.2009.00104.x · Cited by 154

Brain MRI hippocampal volume and prediction of clinical status in a mild cognitive impairment trial

Study, T. A. D. C., Grundman, M., Sencakova, D., Jack, C. R., Petersen, R. C., Kim, H. T., Schultz, A. N., Weiner, M., DeCarli, C. S., DeKosky, S. T., et al. (2002) · Journal of Molecular Neuroscience · doi:10.1007/s12031-002-0006-6 · Cited by 153

Meta-Review of CSF Core Biomarkers in Alzheimer’s Disease: The State-of-the-Art after the New Revised Diagnostic Criteria

Ferreira, D., Perestelo‐Pérez, L., Westman, E., Wahlund, L., Sarría‐Santamera, A., & Serrano‐Aguilar, P. (2014) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2014.00047 · Cited by 153

Cognition, glucose metabolism and amyloid burden in Alzheimer's disease

Furst, A. J., Rabinovici, G. D., Rostomian, A. H., Steed, T., Alkalay, A., Racine, C. A., Miller, B. L., & Jagust, W. J. (2010) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2010.03.011 · Cited by 153

Radiosynthesis, Photoisomerization, Biodistribution, and Metabolite Analysis of 11C-PBB3 as a Clinically Useful PET Probe for Imaging of Tau Pathology

Hashimoto, H., Kawamura, K., Igarashi, N., Takei, M., Fujishiro, T., Aihara, Y., Shiomi, S., Muto, M., Ito, T., Furutsuka, K., et al. (2014) · Journal of Nuclear Medicine · doi:10.2967/jnumed.114.139550 · Cited by 151

Amyloid‐beta plaque growth in cognitively normal adults: Longitudinal [11C]Pittsburgh compound B data

Vlassenko, A. G., Mintun, M. A., Xiong, C., Sheline, Y. I., Goate, A., Benzinger, T. L. S., & Morris, J. C. (2011) · Annals of Neurology · doi:10.1002/ana.22608 · Cited by 148

Clinical Utility and Analytical Challenges in Measurement of Cerebrospinal Fluid Amyloid-β1–42 and τ Proteins as Alzheimer Disease Biomarkers

Kang, J., Korecka, M., Toledo, J. B., Trojanowski, J. Q., & Shaw, L. M. J. (2013) · Clinical Chemistry · doi:10.1373/clinchem.2013.202937 · Cited by 147

Diagnosis of Alzheimer's Disease Based on Disease-Specific Autoantibody Profiles in Human Sera

Nagele, E. P., Han, M. C., DeMarshall, C. A., Belinka, B. A., & Nagele, R. G. (2011) · PLoS ONE · doi:10.1371/journal.pone.0023112 · Cited by 147

Cerebrospinal fluid VILIP-1 and YKL-40, candidate biomarkers to diagnose, predict and monitor Alzheimer’s disease in a memory clinic cohort

Kester, M. I., Teunissen, C. E., Sutphen, C., Herries, E. M., Ladenson, J. H., Xiong, C., Scheltens, P., van der Flier, W. M., Morris, J. C., Holtzman, D. M., et al. (2015) · Alzheimer's Research & Therapy · doi:10.1186/s13195-015-0142-1 · Cited by 146

Positron emission tomography imaging and clinical progression in relation to molecular pathology in the first Pittsburgh Compound B positron emission tomography patient with Alzheimer’s disease

Kadir, A., Marutle, A., Gonzalez, D., Schöll, M., Almkvist, O., Mousavi, M. T., Mustafiz, T., Darreh‐Shori, T., Nennesmo, I., & Nordberg, A. K. (2010) · Brain · doi:10.1093/brain/awq349 · Cited by 145

Cerebrospinal Fluid Concentration of Brain-Derived Neurotrophic Factor and Cognitive Function in Non-Demented Subjects

Li, G., Peskind, E. R., Millard, S. P., Chi, P., Sokal, I., Yu, C., Bekris, L. M., Raskind, M. A., Galasko, D. R., & Montine, T. J. (2009) · PLoS ONE · doi:10.1371/journal.pone.0005424 · Cited by 144

Autoantibodies to amyloid-? and Alzheimer's disease

Hyman, B. T., Smith, C. R., Buldyrev, I., Whelan, C. M., Brown, H., Tang, M., & Mayeux, R. P. (2001) · Annals of Neurology · doi:10.1002/ana.1061 · Cited by 144

IgA NMDA receptor antibodies are markers of synaptic immunity in slow cognitive impairment

Prüss, H., Höltje, M., Maier, N., Gomez, A., Buchert, R., Harms, L., Ahnert-Hilger, G., Schmitz, D., Terborg, C., Kopp, U., et al. (2012) · Neurology · doi:10.1212/wnl.0b013e318258300d · Cited by 143

Three-dimensional surface mapping of hippocampal atrophy progression from MCI to AD and over normal aging as assessed using voxel-based morphometry

Chételat, G., Fouquet, M., Kalpouzos, G., Denghien, I., De la Sayette, V., Viader, F., Mézenge, F., Landeau, B., Baron, J. C., Eustache, F., et al. (2008) · Neuropsychologia · doi:10.1016/j.neuropsychologia.2007.11.037 · Cited by 143

High prevalence of NMDA receptor IgA/IgM antibodies in different dementia types

Doss, S., Wandinger, K., Hyman, B. T., Panzer, J. A., Synofzik, M., Dickerson, B. C., Mollenhauer, B., Scherzer, C. R., Ivinson, A. J., Finke, C., et al. (2014) · Annals of Clinical and Translational Neurology · doi:10.1002/acn3.120 · Cited by 141

Alzheimer's disease cerebrospinal fluid biomarker in cognitively normal subjects

Toledo, J. B., Zetterberg, H., van Harten, A. C., Glodzik, L., Martinez-Lage, P., Bocchio-Chiavetto, L., Rami, L., Hansson, O., Sperling, R., Engelborghs, S., et al. (2015) · Brain · doi:10.1093/brain/awv199 · Cited by 136

Imaging in-vivo tau pathology in Alzheimer’s disease with THK5317 PET in a multimodal paradigm

Chiotis, K., Saint‐Aubert, L., Savitcheva, I., Jelić, V., Andersen, P., Jonasson, M., Eriksson, J., Lubberink, M., Almkvist, O., Wall, A. E., et al. (2016) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-016-3363-z · Cited by 131

[18F]THK-5117 PET for assessing neurofibrillary pathology in Alzheimer’s disease

Harada, R., Okamura, N., Furumoto, S., Furukawa, K., Ishiki, A., Tomita, N., Hiraoka, K., Watanuki, S., Shidahara, M., Miyake, M., et al. (2015) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-015-3035-4 · Cited by 128

Tau in cerebrospinal fluids: establishment of the sandwich ELISA with antibody specific to the repeat sequence in tau

Mori, H., Hosoda, K., Matsubara, E., Nakamoto, T., Furiya, Y., Endoh, R., Usami, M., Shoji, M., Maruyama, S., & Hirai, S. (1995) · Neuroscience Letters · doi:10.1016/0304-3940(95)11291-4 · Cited by 128

Amyloid negativity in patients with clinically diagnosed Alzheimer disease and MCI

Landau, S. M., Horng, A., Fero, A., Jagust, W. J., Initiative, A. D. N., Initiative, A. D. N., Weiner, M. W., Aisen, P., Weiner, M. W., Aisen, P., et al. (2016) · Neurology · doi:10.1212/wnl.0000000000002576 · Cited by 128

Concordance Between Cerebrospinal Fluid Biomarkers and [11C]PIB PET in a Memory Clinic Cohort

Zwan, M. D., van Harten, A. C., Ossenkoppele, R., Bouwman, F. H., Teunissen, C. E., Adriaanse, S. F., Lammertsma, A. A., Scheltens, P., van Berckel, B. N. M., & van der Flier, W. M. (2014) · Journal of Alzheimer s Disease · doi:10.3233/jad-132561 · Cited by 120

No association of CSF biomarkers with APOE 4, plaque and tangle burden in definite Alzheimer's disease

Engelborghs, S., Sleegers, K., Cras, P. P., Brouwers, N., Serneels, S., Leenheir, E. D., Martin, J. J., Vanmechelen, E., Broeckhoven, C. V., & Deyn, P. P. D. (2007) · Brain · doi:10.1093/brain/awm136 · Cited by 114

Imaging Techniques in Alzheimer’s Disease: A Review of Applications in Early Diagnosis and Longitudinal Monitoring

van Oostveen, W. M., & de Lange, E. C. M. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22042110 · Cited by 297

The interplay among oxidative stress, brain insulin resistance and AMPK dysfunction contribute to neurodegeneration in type 2 diabetes and Alzheimer disease

Barone, E., Domenico, F. D., Marzia Perluigi, A., & Butterfield, D. A. (2021) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2021.09.006 · Cited by 182

Biomarkers used in Alzheimer’s disease diagnosis, treatment, and prevention

Mahaman, Y. A. R., Embaye, K. S., Huang, F., Li, L., Zhu, F., Wang, J.-Z., Liu, R., Feng, J., & Wang, X. (2022) · Ageing Research Reviews · doi:10.1016/j.arr.2021.101544 · Cited by 149

The emerging role of exosomes in Alzheimer’s disease

Zhang, T., Ma, S., Lv, J., Wang, X., Afewerky, H. K., Li, H. R., & Lu, Y. (2021) · Ageing Research Reviews · doi:10.1016/j.arr.2021.101321 · Cited by 141

Cerebrospinal fluid biomarkers for understanding multiple aspects of Alzheimer’s disease pathogenesis

Dhiman, K., Blennow, K., Zetterberg, H., Martins, R. N., & Gupta, V. B. (2019) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-019-03040-5 · Cited by 117

Correspondence to:

Dubravka, M. B., Dorotea, Š. Š., Stanić, G., Patrick, R., Šimić, H. G., Brain, F., & Šimić, G. (2014)

Update on the core and developing cerebrospinal fluid biomarkers for Alzheimer disease

Leko, M. B., Štrac, D. Š., Mück‐Šeler, D., Pivac, N., Stanić, G., Hof, P. R., & Šimić, G. (2014) · Croatian Medical Journal · doi:10.3325/cmj.2014.55.347 · Cited by 48

Biomarkers of Alzheimer Disease

Sperling, R. A., & Johnson, K. A. (2013) · CONTINUUM Lifelong Learning in Neurology · doi:10.1212/01.con.0000429181.60095.99 · Cited by 58

Biomarkers in the Early Detection and Diagnosis of Alzheimer's Disease

Rucka, A. M., Kowalski, M., Rucki, M., Cieleban, N., Gajewska, M., & Modliborska, M. (2026) · Journal of Education Health and Sport · doi:10.12775/jehs.2026.94.73121

Role of CSF Biomarkers in the Diagnosis of Prodromal Alzheimer‘s Disease

Parnetti, L., & Chiasserini, D. (2011) · Biomarkers in Medicine · doi:10.2217/bmm.11.48 · Cited by 12